Zhaohui Su, VP of Biostatistics at Ontada, shared a post on LinkedIn:
“Pharma is entering 2026 with significant changes on the horizon. The industry is shifting its focus from broad marketing to personalized care, ensuring that patients receive tailored support and improved coordination between healthcare providers and drug manufacturers. Technology, particularly AI, will play a critical role in enabling companies to operate more efficiently and reduce costs.
A key trend to watch is the rise of real-world evidence (RWE). This approach uses patient data—not just results from clinical trials—to demonstrate how treatments perform in everyday situations. RWE empowers companies to validate value, enhance care, and make informed decisions.
The article below commented that in 2026, success will belong to those who embrace data integration, foster collaboration across the healthcare system, and take bold steps to personalize care and drive innovation.”
More posts featuring Zhaohui Su.